New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status
Dateline City:
KENILWORTH, N.J.
Results from KEYNOTE-012, the First and Largest Study to Date of an Anti-PD-1 Therapy in Head and Neck Cancer, to be Presented at 2015 ASCO Annual Meeting
KEYTRUDA Monotherapy Achieved Overall Response Rate of 25 Percent in Heavily Pre-treated Patients
Merck is Advancing a Broad Head and Neck Clinical Program for KEYTRUDA with Five Clinical Trials, Across Multiple Lines of Therapy and in Combination with Other Agents
...
Source: Merck.com - Product News - May 29, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Merck’s KEYTRUDA® (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine
Dateline City:
KENILWORTH, N.J.
Early Findings Show DNA Mismatch Repair-Deficient Colorectal and Other Tumors Highly Responsive to Checkpoint Blockade with Anti-PD-1 Therapy
Merck Plans to Initiate Phase 2 Registrational Study with KEYTRUDA (KEYNOTE-164) to Evaluate MMR-Deficiency in Colorectal Cancer
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced results from the first study evaluating ...
Source: Merck.com - Product News - May 29, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab)
Dateline City:
KENILWORTH, N.J. & SEATTLE
Collaboration Builds on Merck’s R&D and NanoString’s Biomarker Development Leadership Positions in Immuno-Oncology
Early Data Evaluating Immune-Related Signatures with KEYTRUDA in Multiple Cancers to be Presented for the First Time at 2015 ASCO Annual Meeting
KENILWORTH, N.J. & SEATTLE--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
NanoString Technologies, Inc. (NASDAQ:N...
Source: Merck.com - Product News - May 28, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen
Dateline City:
BERKELEY, Calif., and KENILWORTH, N.J.
Study will Evaluate Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab),
in Combination with Plexxikon’s PLX3397
BERKELEY, Calif., and KENILWORTH, N.J. – Plexxikon Inc., a member of Daiichi Sankyo Group, and Merck (NYSE:MRK), known as MSD outside the US and Canada, through a subsidiary, today announced a collaborative clinical trial that will evaluate the combination of PLX3397, Plexxikon’s investigational CSF-1R inhibitor, and KEYTRUDA® (pembro...
Source: Merck.com - Product News - May 7, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Trial Evaluating Cardiovascular Outcomes with
Sitagliptin (TECOS) of Merck’s DPP-4 inhibitor, JANUVIA®
(sitagliptin), achieved its primary endpoint of non-inferiority for the
composite cardiovascular (CV) endpoint. Among secondary endpoints, there
was no increase in hospitalization for heart failure in the sitagliptin
group versus placebo.
Language:
...
Source: Merck.com - Product News - April 27, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors
Dateline City:
MALVERN, Pa. & KENILWORTH, N.J.
MALVERN, Pa. & KENILWORTH, N.J.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG), a clinical-stage
biopharmaceutical company focused on discovering and developing novel
small molecule therapeutics in oncology and infectious diseases, and
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today they have entered into an oncology clinical study
collaboration.
Language:
English
...
Source: Merck.com - Product News - April 20, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
Early Findings with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting
Dateline City:
PHILADELPHIA
KEYTRUDA Demonstrated 28 Percent Overall Response Rate and 76 Percent Disease Control Rate in Difficult-to-Treat Cancer
First Findings from KEYNOTE-028, Merck’s Innovative Basket Trial in 20 Cancers
PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the first presentation of data investigating the use of
KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy,...
Source: Merck.com - Product News - April 19, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma
Dateline City:
WALTHAM, Mass. & KENILWORTH, N.J.
WALTHAM, Mass. & KENILWORTH, N.J.--(BUSINESS WIRE)--Syndax Pharmaceuticals, Inc., and Merck (NYSE:MRK), known as MSD outside
the United States and Canada, announced today that they have entered
into a clinical trial collaboration to evaluate the safety and efficacy
of combining Syndax’s entinostat, an investigational epigenetic therapy,
with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1
therapy approved in the United States.
Language:
...
Source: Merck.com - Product News - March 31, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN® (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes
Dateline City:
SAN DIEGO
SAN DIEGO--(BUSINESS WIRE)--Merck (NYSE:MRK),
known as MSD outside the United States and Canada, today announced
results from a pre-specified exploratory analysis of the investigational
IMPROVE-IT study of more than 18,000 patients presenting with acute
coronary syndromes.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestor...
Source: Merck.com - Product News - March 16, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY® (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in Certain Patients with Peripheral Arterial Disease
Dateline City:
KENILWORTH, N.J.
These and other post-hoc subgroup analyses from TRA-2°P are being presented at the 2015 American College of Cardiology Scientific Sessions
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK),
known as MSD outside the United States and Canada, today announced
results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin
Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic
Events) trial of ZONTIVITY® (vora...
Source: Merck.com - Product News - March 5, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer
Dateline City:
TOKYO & KENILWORTH, N.J.
Combination clinical studies of lenvatinib, eribulin and pembrolizumab to be explored
TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)--Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the U.S. and
Canada, through a subsidiary, announced today a clinical trial
collaboration to evaluate the safety, tolerability and efficacy of
Merck’s anti-PD-1 therapy, pembrolizumab (marketed in the U.S. under the
brand name KEYTRUDA®)...
Source: Merck.com - Product News - March 4, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe/simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions
Dateline City:
KENILWORTH, N.J.
Investigational data from IMPROVE-IT to be announced in Featured Clinical Research Session II
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that new data from two trials of the company’s
cardiovascular medicines will be presented at the 2015 American College
of Cardiology Annual Scientific Sessions (ACC.15), March 14-16 in San
Diego.
Language:
...
Source: Merck.com - Product News - February 25, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck Announces Collaboration with the Medicines Patent Pool to Expand Access to Pediatric Formulations of Raltegravir in Developing Countries
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced an agreement with the Medicines Patent Pool (MPP) to
license its pediatric formulations of raltegravir for use in treating
HIV-1 infection in infants and children from four weeks to under 12
years of age in developing countries. This is the MPP’s first agreement
to provide access to an HIV integrase inhibitor for use in combination
HIV therapy for infants and children in thi...
Source: Merck.com - Product News - February 24, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
FDA Approves Merck's HPV Vaccine, GARDASIL®9, to Prevent Cancers and Other Diseases Caused by Nine HPV types – Including Types that Cause About 90% of Cervical Cancer Cases
Dateline City:
KENILWORTH, N.J.
GARDASIL 9 includes the greatest number of HPV types in any available HPV vaccine
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the U.S.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Deb Wambold, 215-652-2913orInvesto...
Source: Merck.com - Product News - December 11, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Vaccine News Corporate News Latest News Source Type: news
